So you’ve stopped taking GLP-1s. Now what happens?
GLP-1 receptor agonists have transformed obesity treatment, providing many individuals with clinically meaningful weight loss and improvements in blood sugar, blood pressure, and other cardiometabolic markers. But what happens when the prescription ends?
Whether due to insurance coverage, cost, side effects, or personal preference, many people may eventually stop taking medications like semaglutide and tirzepatide. And while stopping may be the right choice for some, it’s important to understand what typically happens next, and why it underscores the need for comprehensive, ongoing support.
Obesity is a chronic, relapsing condition
The American Board of Obesity Medicine (ABOM) provides rigorous training in the complexities of obesity, from the biological Unlike an acute illness, obesity doesn’t resolve with a single intervention. It’s a complex, chronic disease influenced by genetics, hormones, environment, and behavior. While GLP-1s are highly effective at helping people lose weight and improve metabolic health, they cannot change the underlying biology that predisposes someone to regain weight.
“GLP-1 therapies may be among the most revolutionary drugs of our generation, when managed correctly,” Says Dan Hulverson, our VP of Enterprise Solutions. “But here’s the catch: power without structure introduces risk. GLP-1s are metabolic amplifiers, not lifestyle replacements. Mismanaged use can be extremely costly, damaging, and economically counterproductive, leading to lean mass loss, malnutrition, orthostatic events, injury, poor adherence, and rebound weight gain.”That’s why organizations, including the Obesity Society and American Association of Clinical Endocrinology, continue to emphasize the importance of long-term care, not just for weight loss, but for weight maintenance and overall cardiometabolic health. GLP-1s have proven to be clinically transformative in this regard. When used appropriately, they are not only effective at reducing excess weight but also at lowering the risk of serious complications like heart disease, stroke, and type 2 diabetes. As a result, they are increasingly seen as cost-effective, helping reduce hospitalizations, disease progression, and the long-term burden on the healthcare system.
New evidence: what the data tells us about stopping GLP-1s
A 2026 systematic review and meta-analysis published in The BMJ offers one of the clearest pictures to date of what typically happens after anti-obesity medications are discontinued. The study analyzed 37 clinical trials with over 9,300 adults and found a consistent pattern of weight regain after treatment cessation.
Here are the key takeaways:
- On average, individuals regained 0.4 kg (about 0.88 lbs) per month after stopping medication.
- Most people returned to their baseline body weight within approximately 1.7 years.
- Cardiometabolic improvements, including blood sugar, blood pressure, and cholesterol, also trended back toward pre-treatment levels within 1.4 years.
- Notably, weight regain was faster in people who had been on GLP-1 medications compared to those who had only undergone lifestyle interventions.
In short, when GLP-1 therapy ends, the body often resumes its previous trajectory. Appetite returns, energy balance shifts, and the biological drive to regain weight reactivates. This isn’t a failure of willpower; it’s physiology.
Why does weight come back?
GLP-1 medications work by enhancing satiety, reducing appetite, slowing gastric emptying, and, in some cases, improving insulin sensitivity. When the medication is discontinued, these effects diminish. Hunger cues often increase, cravings return, and it becomes harder to maintain the same level of food intake or lifestyle change that was sustainable while on therapy.
Additionally, many people experience weight loss while on medication without developing the durable habits or support systems needed for maintenance. Without a structured plan in place, even small changes in behavior, like less physical activity and emotional eating, can heighten the biological drive to regain weight.
What this means for your employees
For individuals transitioning off GLP-1s, these findings can feel discouraging, but they also offer a powerful opportunity. By planning for the transition and equipping individuals with the right tools and support, we can help deter weight regain and preserve the health benefits achieved during treatment.
This is where whole-person care becomes essential.
Why wraparound solutions matter
Medication alone was never meant to carry the full burden of obesity treatment. The best outcomes occur when GLP-1s are embedded within a broader ecosystem of care. One that includes behavior change, nutrition counseling, mental health support, and physical activity guidance.
At Vida, we’ve seen how wraparound care can stabilize progress even after medication ends. Our model provides:
- Personalized nutrition coaching to help individuals build sustainable eating patterns adapted to their real-world needs.
- Cognitive behavioral therapy and emotional support to manage stress, triggers, and the mental health aspects of obesity.
- Activity planning that’s realistic, accessible, and tailored to each person’s abilities and lifestyle.
- Ongoing clinical monitoring and care coordination to ensure safe transitions and early intervention if weight begins to return.
Importantly, this kind of support helps people feel equipped and empowered rather than abandoned when their prescription ends.
We must be proactive in our solutions
Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. At Vida, it is our belief that once a patient has achieved their clinical objectives and maintained them for at least 6 months in order to have a degree of both physiologic and behavioral stability, the patient should then be offered the opportunity to wean, discontinue, or transition to an oral agent. For those patients who wish to transition, we redeploy our behavior change supports to ensure a successful transition.. All to say, we believe everyone deserves support before, during, and after treatment.
The data is clear: weight and cardiometabolic outcomes often revert when support is withdrawn. But the future doesn’t have to look like the past. When people are surrounded by care that addresses their full experience, not just the number on the scale, they’re more likely to sustain progress over time.
The path off GLP-1s doesn’t have to lead back to square one. With evidence-based, whole-person care, it can be a new chapter, one where people are no longer relying on a single solution, but building the foundation for long-term, metabolically healthy lives.
